Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $235.8 million.

  • Tg Therapeutics' Cash & Current Investments fell 3085.85% to $235.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.8 million, marking a year-over-year decrease of 3085.85%. This contributed to the annual value of $311.0 million for FY2024, which is 4298.32% up from last year.
  • Per Tg Therapeutics' latest filing, its Cash & Current Investments stood at $235.8 million for Q3 2025, which was down 3085.85% from $401.6 million recorded in Q2 2025.
  • Tg Therapeutics' Cash & Current Investments' 5-year high stood at $523.8 million during Q1 2021, with a 5-year trough of $139.7 million in Q1 2023.
  • In the last 5 years, Tg Therapeutics' Cash & Current Investments had a median value of $233.2 million in 2022 and averaged $277.6 million.
  • Per our database at Business Quant, Tg Therapeutics' Cash & Current Investments skyrocketed by 56872.79% in 2021 and then crashed by 5586.76% in 2022.
  • Tg Therapeutics' Cash & Current Investments (Quarter) stood at $314.8 million in 2021, then tumbled by 48.64% to $161.7 million in 2022, then skyrocketed by 34.53% to $217.5 million in 2023, then surged by 42.98% to $311.0 million in 2024, then fell by 24.18% to $235.8 million in 2025.
  • Its Cash & Current Investments was $235.8 million in Q3 2025, compared to $401.6 million in Q2 2025 and $420.3 million in Q1 2025.